ATR and cancer: Moreover, mice with Seckel syndrome crossed with p53-deficient mice are not cancer-prone [103] and ATR has been shown to support homologous recombination repair (HRR) [63,104], which provides the rationale for developing ATR inhibitor as anticancer treatments.